Shots:

• Charles River Laboratories to acquire Vigene in all cash transaction for $292.5M. In addition to the initial purchase price- the transaction includes contingent additional payments of up to $57.5M based on future performance
• The transaction is expected to be close in Q3’21. The acquisition will allow Charles River to boost its gene therapy capabilities in the high-growth- value-added cell- and gene therapy CDMO sector
• Vigene is expected to improve Charles River’s reported revenue growth rate by ~50 basis points in 2021. The acquisition complements Charles River’s existing non-clinical development and manufacturing portfolio

  Ref: Business Wire | Image: Pharma Advancement